High-throughput SARS-CoV-2 genetic diagnostics

Hyrax Biosciences’ Exatype platform is a user-friendly, high-throughput data-analysis pipeline that provides automated analysis, interpretation and reporting for sequencing-based diagnostics.

Our COVID-19 solution supports SARS-CoV-2 NGS diagnostic testing as well as genotyping for research and surveillance.

In order to support the global effort to track and understand the COVID-19 pandemic, we have partnered with Amazon Web Services (AWS) to provide free analysis of SARS-CoV-2 sequence data generated using the ARTIC protocols (https://artic.network/ncov-2019).

Click here for a free trial

*Example NGS datasets included in the welcome email.

Making genotyping easy

Sequence-based COVID-19 genotyping offers the potential to know more about transmission routes, guide and monitor interventions, as well as understand the viral adaptation such as detecting potential resistance to treatments.

The Exatype SARS-CoV-2 solution makes this process simple, accurate and fast. Fully automated analysis of SARS-CoV-2 sequence data takes raw NGS reads and outputs insightful results.

Outputs include:

  • Quality control information about your sequence data.
  • Tables showing nucleotide variants relative to the reference sequence.
  • Consensus sequence for each sample.
  • Batch download of results.
Overview of the read coverage across the SARS-CoV-2 genome for all samples in a job.
Overview of the read coverage across the SARS-CoV-2 genome for all samples in a job.
Results can be explored through a user-friendly interface.
Results can be explored through a user-friendly interface.

Tailor your analysis workflow to your needs

It is easy to integrate Exatype into you or your customer’s workflow with a variety of access options:

  • Upload sequence data and view results through an easy to use drag-and-drop web interface.
  • Intuitive APIs allow for integration with sequencing machines for data upload and with LIMS for result presentation for high throughput requirements.
  • Fully dockerised solutions available for local, offline use.

Scalable, integrated diagnostic testing

Sequencing-based COVID-19 diagnostic tests offer the capability to simultaneously sequence thousands of samples with high sensitivity and accuracy providing detection to as low as a single viral copy in a sample.

The Exatype platform is designed to enable such diagnostics through direct integration with sequencing machines and LIMS systems for fully “hands off” analysis and reporting at scale:

  • Tailored to your needs: Our solution can be deployed in the cloud or as a solution for local, offline use.
  • Built for scale: An unlimited number of samples can be processed in parallel in the cloud with no end-user input needed.
  • Accuracy: Exatype’s algorithms have a proven capacity for highly accurate mapping and variant calling in viral data.
  • Customizable: our modularised platform means we can rapidly deploy as companion software for any SARS-CoV-2 diagnostic assay.
  • Expandable: You are not limited to detecting SARS-CoV-2! We can support panels targeting the detection and differentiation of SARS-CoV-2 from other infections (e.g. influenza).

For more information contact us at info@hyraxbio.com.

Hyrax Biosciences

At Hyrax Biosciences we strive to make precision medicine universally accessible through the development of accurate, easy-to-use software for genetic diagnostics. Exatype, our flagship product, provides an intuitive and scalable platform for the development and widespread deployment of sequencing-based diagnostics. We work with researchers, diagnostic laboratories, assay developers, national surveillance programs and sequencing companies to achieve this goal. We enable our partners and their customers to undertake automated sample-to-report diagnostics with unprecedented accuracy and scale.